

Giulia Parisi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3435522/publications.pdf>

Version: 2024-02-01

10
papers

2,923
citations

1040056

9
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

6772
citing authors

#	ARTICLE	IF	CITATIONS
1	Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Reports, 2017, 19, 1189-1201.	6.4	1,256
2	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. Cancer Discovery, 2017, 7, 188-201.	9.4	997
3	Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science, 2018, 359, 1037-1042.	12.6	254
4	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunology Research, 2016, 4, 845-857.	3.4	110
5	Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discovery, 2020, 10, 1140-1157.	9.4	97
6	Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Science Translational Medicine, 2020, 12, .	12.4	77
7	Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nature Communications, 2020, 11, 660.	12.8	68
8	MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Oncotarget, 2017, 8, 17795-17809.	1.8	35
9	IL-32 ^{Δ3} potentiates tumor immunity in melanoma. JCI Insight, 2020, 5, .	5.0	20
10	IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. Clinical Cancer Research, 2019, 25, 1000-1011.	7.0	9